Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis breakthrough? two simple Add-Ons may cut deadly complications

NCT ID NCT07335471

Disease control Sponsor: Suzhou Municipal Hospital of Anhui Province Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two extra treatments for people on dialysis for kidney failure. One adds a special filter (hemoperfusion) to clean more toxins from the blood, aiming to reduce heart and brain complications. The other gives a steady sugar solution during dialysis to help patients who get dangerously low blood pressure. The trial involved 100 adults and checked if these methods improve safety and comfort during treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hemoperfusion and continuous high-glucose infusion
What this could lead to
If successful, these approaches could help dialysis patients have fewer heart and brain problems, and make dialysis sessions safer and more comfortable.
What could go wrong
This is a small, single-center study with only 100 participants, so results may not apply to everyone. Risks include bleeding, infection, and blood sugar changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 80 years. 2. Receiving maintenance hemodialysis (MHD) for 3 months or longer. 3. Diagnosis of severe ultrafiltration intolerance (UFI), defined as either: Persistent pre-dialysis hypotension (systolic blood pressure \<100 mmHg), OR Recurrent intradialytic hypotension (IDH), defined per KDOQI guidelines as a decrease in systolic blood pressure to \<90 mmHg or by \>20 mmHg from baseline, accompanied by symptoms. 4. Failure to achieve target ultrafiltration volume (mean UFV \<1.5 L per session) despite at least 4 weeks of conventional interventions (e.g., dialysate cooling, sodium profiling, sequential ultrafiltration). 5. Inadequate dialysis delivery, defined as a mean single-pool Kt/V of less than 1.2. Exclusion Criteria: 1. Acute infection, myocardial infarction, or major surgery within the past 3 months. 2. Uncontrolled diabetes mellitus, defined as a glycated hemoglobin (HbA1c) level greater than 9%. 3. Severe liver dysfunction (Child-Pugh class C).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases (CVD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome cardiovascular disorder cerebrovascular disorder uremia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases (CVD) Cerebrovascular disorders Dialysis adequacy Intradialytic hypotension Ultrafiltration intolerance Uremia; chronic

Contacts and locations

Locations

  • Blood Purification Center, Suzhou Hospital Affiliated to Anhui Medical University

    Suzhou, Anhui, 234000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.